相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
Peter Ferenci et al.
GASTROENTEROLOGY (2008)
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
Alessandra Mangia et al.
HEPATOLOGY (2008)
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
Olav Dalgard et al.
HEPATOLOGY (2008)
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
Sanaa M. Kamal et al.
HEPATOLOGY (2007)
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
Bart J. Veldt et al.
ANNALS OF INTERNAL MEDICINE (2007)
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2007)
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:: A randomized controlled trial
Vito Di Marco et al.
JOURNAL OF HEPATOLOGY (2007)
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
Mitchell L. Shiffman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response?
B. Willems et al.
JOURNAL OF HEPATOLOGY (2007)
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study
Savino Bruno et al.
HEPATOLOGY (2007)
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
Joseph F. Perz et al.
JOURNAL OF HEPATOLOGY (2006)
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
DM Jensen et al.
HEPATOLOGY (2006)
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
S Zeuzem et al.
JOURNAL OF HEPATOLOGY (2006)
Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis
F Marrache et al.
JOURNAL OF VIRAL HEPATITIS (2005)
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
A Mangia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival
Y Shiratori et al.
ANNALS OF INTERNAL MEDICINE (2005)
Global epidemiology of hepatitis C virus infection
CW Shepard et al.
LANCET INFECTIOUS DISEASES (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
O Dalgard et al.
HEPATOLOGY (2004)
Empirically calibrated model of hepatitis C virus infection in the United States
JA Salomon et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
EJ Heathcote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
